Acurx Pharmaceuticals, Inc. Total Liabilities and Equity
Acurx Pharmaceuticals, Inc. (ACXP) had Total Liabilities and Equity of $10.98 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $10.98M.
- 2026-03-31: Liabilities and Equity $9.54M.
- 2025-12-31: Liabilities and Equity $7.69M.
- 2025-09-30: Liabilities and Equity $6.11M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $10.98M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $9.54M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $7.69M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $6.11M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $6.16M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.81M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $3.86M 10-K · filed 2026-03-12 |
| 2024-09-30 | $5.98M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.58M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $9.11M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $7.71M 10-K · filed 2025-03-17 |
| 2023-09-30 | $7.16M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $9.24M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $7.39M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $9.38M 10-K · filed 2024-03-15 |
| 2022-09-30 | $10.95M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $9.26M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $11.32M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $13.25M 10-K · filed 2023-03-15 |
| 2021-09-30 | $14.99M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $17.44M 10-Q · filed 2021-08-13 |
| 2020-12-31 | $3.22M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |